Cellular markers for dysregulated IgG4 responses in patients with IgG4-related disease Background: IgG 4 -related disease (IgG 4 -RD) is a systemic fibroinflammatory condition affecting various organs and has a diverse clinical presentation. Fibrosis and accumulation of IgG 4 1 plasma cells in tissue are hallmarks of the disease, and IgG 4 -RD is associated with increased IgG 4 serum levels. However, disease pathogenesis is still unclear, and these cellular and molecular parameters are neither sensitive nor specific for the diagnosis of IgG 4 -RD. Objective: Here we sought to develop a flow cytometric gating strategy to reliably identify blood IgG 4 1 B cells to study their cellular and molecular characteristics and investigate their contribution in disease pathogenesis. Methods: Sixteen patients with histologically confirmed IgG 4 -RD, 11 patients with sarcoidosis, and 30 healthy subjects were included for 11-color flow cytometric analysis of peripheral blood for IgG 4 -expressing B cells and T H subsets. In addition, detailed analysis of activation markers and chemokine receptors was performed on IgG 4 -expressing B cells, and IgG 4 transcripts were analyzed for somatic hypermutations. Results: Cellular and molecular analyses revealed increased numbers of blood IgG 4 1 memory B cells in patients with IgG 4 -RD. These cells showed reduced expression of CD27 and CXCR5 and increased signs of antibody maturation. IgG 4 -related disease (IgG 4 -RD) is defined as a systemic fibroinflammatory condition that can affect potentially any organ but predominates in the retroperitoneal space, thyroid, pancreas, salivary glands, and orbital tissue. 1, 2 The pathology is characterized by fibrosis and infiltration of IgG 4 -producing plasma cells of the affected organs. 3, 4 As a result, a tumor-like swelling of the involved organ can occur, which causes organ dysfunction and, if left untreated, can lead to organ failure. Furthermore, AA amyloidosis can develop in patients with IgG 4 -RD, emphasizing the need for prompt diagnosis and treatment of the disease. 5 Previously, diseases with IgG 4 1 plasma cell infiltrates were defined predominantly by organ involvement, and only since 2012 have these diverse manifestations been recognized as one disease entity. 3, 4 The pathogenesis of IgG 4 -RD remains poorly understood. It is thought to be triggered by organ damage, resulting from, for example, a bacterial infection with molecular mimicry or from an underlying autoimmune process. 1 In patients with pancreatic involvement, autoantibodies directed against self-antigens have been observed. 6, 7 Importantly, IgG 4 1 plasma cell infiltrates are not monoclonal, 8 and serum IgG 4 in patients is polyclonal with reactivity to multiple antigens. 9 The function of IgG 4 antibodies remains elusive because these display weak or negligible binding to both C1q and Fcg receptors. 10, 11 Furthermore, IgG 4 molecules have the exclusive ability to exchange Fab arms, thus creating monovalent bispecific antibodies that can prevent immune complex formation. 12 Therefore IgG 4 has a presumed immune-dampening effect; however, its role in the pathogenesis of IgG 4 -RD is controversial. 13 Immunoglobulin class-switching of B cells to IgG 4 is regulated by T H 2 cytokines and IL-10 produced by regulatory T (Treg) cells. 14, 15 Substantial evidence indicates that T H 2 and Treg cells are involved in the pathophysiology of IgG 4 -RD. [16] [17] [18] Affected tissues express higher mRNA levels of the T H 2 cytokines IL-4, IL-5, and IL-13. 16, 17 Furthermore, isolated circulating CD4 1 T cells from patients predominantly produce T H 2 cytokines. 18, 19 Similarly, IL-10 and TGF-b transcripts are increased in affected tissues, 16 and patients with IgG 4 -related autoimmune pancreatitis have increased frequencies of circulating Treg cells. 20, 21 More recently, in affected tissue and blood of patients with IgG 4 -RD, clonal expansions of CD4 effector memory T (TEM) cells have been identified, which potentially drive fibrosis and IgG 4 production. 22, 23 Clinically, IgG 4 -RD manifestations can mimic those of many infectious, inflammatory, and malignant disorders. [24] [25] [26] [27] [28] [29] [30] Therefore diagnosis of IgG 4 -RD can be challenging, often leading to a delay in the start of proper treatment. The gold standard for diagnosis is histology. 28, 31 Characteristic lymphoplasmacytic infiltrates rich in IgG 4 1 plasma cells, storiform fibrosis (cartwheel arrangement of fibroblasts), and obliterative phlebitis are seen in histologic samples. 28 An increase in serum IgG 4 levels supports the diagnosis but is found in only 50% to 70% of patients with histologically proved IgG 4 -RD. 32, 33 Recently, circulating plasmablasts have been postulated as a more reliable marker for the disease, irrespective of IgG 4 serum levels. 34 However, the specificity of this marker is limited because numbers of circulating plasmablasts are also increased in patients with active infection after vaccination and in those with other chronic diseases, such as systemic lupus erythematosus. [35] [36] [37] [38] Still, the importance of B cells in the pathophysiology of the disease is illustrated by recent observations demonstrating that B-cell depletion with rituximab is a promising therapy in patients with IgG 4 -RD. [39] [40] [41] [42] Because rituximab specifically binds CD20, it does not directly target IgG 4 1 plasma cells, which do not express CD20. Thus the therapeutic effect could lie in depletion of memory B cells that are chronically stimulated to generate IgG 4 1 plasma cells. Furthermore, other chronically activated B cells might be involved in the disease through antigen presentation and cytokine production, such as CD21 low B cells that are found to be expanded in patients with diverse chronic inflammatory diseases. 43 Despite previously reported expansions of IgG 4 1 plasma cells, CD4 TEM, T H 2, and Treg cells in affected tissue, little is known about the pathogenesis of IgG 4 -RD. Therefore we developed a new flow cytometric approach that enabled us to study IgG 4 -expressing B cells and their pathogenic contribution to the disease. Our insights into IgG 4 -expressing B cells in combination with abnormalities in B-and T-cell subsets reveal abnormal systemic immune regulation, which are valuable for the improvement of diagnosis and treatment of IgG 4 -RD.
METHODS Patients
Patients with IgG 4 -RD and patients with sarcoidosis were recruited after obtaining signed informed consent from the Immunology Outpatient Clinic at the Erasmus Medical Center Rotterdam and from the Rotterdam Eye Hospital. All patients were older than 18 years and given a diagnosis based on clinical, serologic, and histopathologic findings. All patients with IgG 4 -RD met the IgG 4 -RD diagnostic guidelines, including histologic confirmation, 28 and did not have a known history of an immunodeficiency or any autoinflammatory disease other than IgG 4 -RD. All but 2 patients with sarcoidosis had tissue biopsy-confirmed disease with the typical presence of noncaseating granulomatous inflammation. In 2 patients the diagnosis was based on clinical presentation and supportive serologic parameters (angiotensin-converting enzyme and soluble IL-2 receptors) in combination with radiologic imaging. Healthy control subjects were recruited from healthy subjects selected from department staff, and the control group was age and sex matched to the patient cohort. None of the healthy subjects showed signs of active inflammatory disease. This study was performed according to the Declaration of Helsinki and was approved by the Medical Ethics Committee of Erasmus MC (ethics approval nos. MEC-2014-476, MEC-2015-200, and MEC-2017-084).
Histopathology
All patients with IgG 4 -RD were given a histologic diagnosis. Hematoxylin and eosin stainings were analyzed at the Department of Pathology of the Erasmus Medical Center Rotterdam by a trained pathologist with experience in 
IgG serology
IgG subclass serum levels were measured by using immunonephelometry with a Siemens BN II nepholometer (Siemens, Munich, Germany), according to the manufacturer's guidelines. A possible prozone effect for IgG 4 levels was excluded through dilution of serum samples until reliable values were obtained. 44 
Flow cytometry of blood samples
Patients and control subjects were included over a time period of 3 years. Standardized sample preparation, antibody staining, and flow cytometer instrument settings were used to ensure consistency in flow cytometry. 45 In short, absolute counts of CD3 1 T cells, CD19 1 B cells, and CD16 46 in combination with IGHG4-specific (59GGGCATGATGGGCAYGGGGGACCATA; first round) and IGHGconsensus (59CACGCTGCTGAGGGAGTAG; second round) reverse primers. PCR products were cloned into a pGEMT easy vector (Promega, Madison, Wis), amplified by using colony PCR, and sequenced on an ABI Prism 3130XL (Applied Biosystems, Foster City, Calif). The sequences were analyzed with the IMGT database (www.imgt.org) and BASELINe program (selection.med.yale.edu/baseline).
47,48

Statistical analysis
Frequencies and absolute cell numbers assumed a non-Gaussian distribution. All results are expressed as median values with interquartile ranges, if applicable. Results were analyzed by using the nonparametric Mann-Whitney U test. Linear regression was used to study the strength of association between cell subsets with Spearman r values to measure significance. All P values are 2-tailed and were considered statistically significant if values were less than .05. Statistical analysis was performed with GraphPad Prism software (version 6; GraphPad Software, La Jolla, Calif). Principal component analysis (PCA) was performed with Infinicyt software (Cytognos, Salamanca, Spain). Specificity and sensitivity were calculated with SPPS software (IBM SPSS Statistics 21.0, Armonk, NY).
RESULTS
Patients' characteristics
A total of 16 patients with IgG 4 -RD were included, with a mean age of 56 years (range, 18-79 years) and a male/female ratio of 2:1 (Table I ). All patients were confirmed to have IgG 4 -RD based on the Boston consensus, with typical histopathologic characteristics and the presence of IgG 4 -producing plasma cells in affected tissue (Fig 1) . Twelve of 16 patients had increased serum IgG 4 levels (mean, 5.06 g/L; range, 0.27-25.25 g/L). Four of these patients had an additional increase in serum IgG 1 or IgG 2 levels, and 1 patient with normal serum IgG 4 levels had increased IgG 1 and IgG 3 levels (see Table E3 in this article's Online Repository at www.jacionline.org). Six patients showed signs of active disease based on clinics and increased C-reactive protein levels, erythrocyte sedimentation rates, or both (Table I) . The majority of patients with IgG 4 -RD were treatment naive (no prior treatment), 3 patients had received immunomodulatory medication in the past (medication had been stopped for > _6 months before inclusion), and only 2 patients received low-dose prednisone (Table I) . Most patients had normal counts of blood leukocytes and lymphocytes (see Table E3 ). Increased lymphocytes resulted from high T-cell counts, often in combination with high B-cell and/or natural killer cell numbers. One of the 2 patients treated with prednisone had decreased numbers of B and T cells. In the analysis of the distribution of IgG subclasses within the total IgG memory B-cell compartment, we analyzed material from 15 of the 16 patients.
Of the 11 patients with sarcoidosis, 1 patient used hydroxychloroquine (Plaquenil, Sanofi-Aventis, Paris, France).
All other patients were therapy naive (see Table E4 in this article's Online Repository at www.jacionline.org). All patients had normal leukocyte counts, although some had slightly decreased or slightly increased T-or B-cell counts. One patient had an increased IgG 4 serum level accompanied by an increased IgG 1 serum level. One patient had a slightly decreased IgG 4 serum level, and from 1 patient, IgG serum levels were not determined. Five patients had signs of active disease based on C-reactive protein, erythrocyte sedimentation rate, or both (see Table E4 ).
Immunophenotypical analysis of IgG 4 -expressing B cells
The hallmark of IgG 4 -RD is accumulation of IgG 4 -producing plasma cells in affected tissue. To study whether patients had systemic abnormalities in IgG 4 -expressing B cells, we developed a reliable flow cytometric gating strategy to distinguish cells expressing one of the 4 IgG subclasses (Fig 2, A) . (Fig 2, A) .
To confirm the activated nature and memory phenotype of all IgG 1 B-cell subsets, we studied expression of the B7 family members CD80 and CD86 and the TNF receptor superfamily member transmembrane activator and CAML interactor. All 4 IgG-subclass expressing B-cell subsets showed higher expression of activation markers than naive B cells (Fig 2, B) , fitting with an activated memory B-cell phenotype.
Increased CD21
low B-cell and plasmablast numbers but reduced IgM 1 IgD 1 memory B-cell numbers in patients with IgG 4 -RD To study systemic abnormalities in IgG 4 -expressing B cells, we performed extensive immunophenotyping of B cells in 16 patients with IgG 4 -RD and compared these with 30 age-matched healthy control subjects (Fig 3, A) . The median numbers of transitional and naive mature B cells were not different between patients and control subjects. Of the 6 major memory B-cell subsets, only the IgM 
IgD
1 memory B cells were significantly affected in patients (reduced; P < .05; Fig 3, B) . In contrast, numbers of CD21 low B cells (CD19 
CD27
1 ) were significantly higher in patients with IgG 4 -RD (both P < .05).
Patients with IgG 4 -RD have increased numbers of IgG 4 1 memory B cells
Despite normal total numbers of IgG 1 memory B cells, patients with IgG 4 -RD had significantly higher numbers of IgG 4 1 memory B cells than control subjects (P < .01; Fig 3, C) . In addition, patients had reduced numbers of memory B cells expressing IgG 1 (P < .05), whereas IgG 2 -and IgG 3 -expressing B-cell numbers were similar to those in control subjects (see Fig E1, A, in this article's Online Repository at www.jacionline. org). When analyzed as a fraction of total IgG-expressing memory B cells, the decrease in IgG 1 and increase in IgG 4 levels in patients with IgG 4 -RD became more apparent (both P <.0001). Furthermore, patients with IgG 4 -RD showed a significant increase in the fraction of IgG memory B cells expressing IgG 2 (P < .01).
To study whether there was a direct relation with serum IgG 4 levels, we performed linear regression analyses with the percentages and absolute numbers of IgG 4 1 memory B cells (see Fig E1, B) . These did not reveal significant correlations, indicating that memory B-cell numbers and serum IgG 4 levels were not directly related.
Because both IgG 4 -expressing and CD21 low B-cell numbers were significantly increased in patients with IgG 4 -RD, we studied whether these were related and investigated CD21 low B cells expressing IgG 4 (see Fig E1, C) . Indeed, patients carried significantly more CD21 low IgG 4 1 B cells (see Fig E1, D) , and these numbers were directly correlated to the total number of CD21 low B cells (P < .01; see Fig E1, E) .
Cellular and molecular analysis of IgG 4 -expressing B cells in patients with IgG 4 -RD
To analyze the nature of the IgG 4 -expressing B-cell expansion in patients with IgG 4 -RD, we first studied expression of CD27 ( Fig 4, A) . In healthy control subjects the frequencies of cells that expressed CD27 were highest within the IgG 2 and IgG 4 subsets, followed by IgG 1 and IgG 3 (Fig 4, B) . Thus CD27 positivity was greater in cells using IgG subclasses encoded by the downstream genes within the IGH locus (Cg2 and Cg4; Fig 4, C) . 
MFI IL4R 1 memory B cells from healthy subjects and patients with IgG 4 -RD (Fig 4, D) . In contrast, CXCR5 expression was significantly lower on IgG 4 1 memory B cells from patients. To investigate the nature of the expanded IgG 4 1 memory B cells in the pathogenesis of IgG 4 -RD, we studied somatic hypermutations (SHMs) in the IGHV regions (Fig 4, E) . Such mutations are molecular signs of B-cell responses and affinity maturation. 49 In agreement with previous studies, SHM frequencies in IgG 4 transcripts of healthy adults were higher than in the more proximally encoded IgG 1 and IgG 2 (see Fig E2, A) .
50,51 SHM levels in IgG 4 transcripts of patients with IgG 4 -RD (7.89%) were similarly high as those in healthy adults (7.98%, P 5 .75; Fig 4, F) .
To study whether the mutations were driven by selection for antigen binding, we analyzed the selection for replacement mutations in the complementarity-determining regions (CDRs) with the Bayesian estimation of the Antigen-driven Selection program BASELINe. 48 IgG 4 transcripts from healthy control subjects did not show more replacement mutations than expected by random chance in the CDR regions (ie, absence of positive selection; Fig 4, G) . 48 In contrast, CDR regions of patients with IgG 4 -RD showed positive selection for replacement mutations. Both groups showed normal negative selection for replacement mutations in framework regions that compose the structure of the variable domain. Thus IgG 4 1 B cells in patients with IgG 4 -RD show increased selection for replacement mutations in CDR regions. Patients and control subjects displayed high diversity in the sequence and length of the CDR3 region, which is encoded by the junction of the V, D, and J genes. Still, patients showed significantly shorter IGH-CDR3 regions in IgG 4 transcripts than healthy subjects (see Fig E2, B) . Furthermore, IGHV use seemed to differ between groups, with increased use of IGHV5-51 in patients with IgG 4 -RD and reduced IGHV3-39 use (see Fig E2,  C) , although this did not reach statistical significance (P 5 .08). (Fig 5, A) . Flow cytometric immunophenotyping of blood T cells demonstrated normal overall numbers of naive, central memory, and effector memory CD4 T cells (see Fig E3, , P < .001) than healthy subjects (Fig 5, B) . T H 1 cell counts seemed slightly lower, but this was not significant, and numbers of follicular helper T cells and T H 17 cells were not different. Linear regression showed a direct correlation between numbers of IgG 4 1 memory B cells and T H 2 cells (P < .01) but not for Treg cells (P 5 .24; Fig 5, C) . CD21 low IgG4 1 B-cell numbers were similarly correlated with T H 2 cell numbers (P < .05) but not with Treg cell numbers (P 5 .49; see Fig E3, A) . IgG 4 serum levels in patients did not correlate with T H 2 or Treg cell numbers (see Fig E3, B) . In contrast to the changes in T H cell subsets, patients with IgG 4 -RD had no differences in numbers of CD4
2 TEMRO cells (CD4 CTLs; see Fig E4, A and B, in this article's Online Repository at www.jacionline.org). Finally, naive CD8 T-cell numbers were decreased in patients with IgG 4 -RD in the absence of effector memory expansions (see Fig E4, C) .
Skewing of T H subsets toward T H 2 is also observed in patients with allergies and frequently accompanied by eosinophilia. 52 However, we did not find increased numbers of eosinophils (SSC high CD45 
IgG4
1 memory B cells and other lymphocyte subsets as a diagnostic tool for IgG 4 
-RD
Despite clinical indications and high serum IgG 4 levels, diagnosis of IgG 4 -RD requires analysis of a tissue biopsy specimen. Obtaining a biopsy specimen can be difficult, is invasive, is sample error sensitive, and might not always be sufficiently discriminative from other immunoproliferative and autoinflammatory diseases. A specific blood marker could be a valuable means to overcome these diagnostic challenges. However, the differences in B-and T-cell subsets we identified do not provide a clear discrimination between patients and control subjects. Therefore we explored whether a combination of measurements could be used as a disease marker.
First, we performed PCA on the absolute cell numbers of all Band T-cell subsets from healthy subjects and patients with IgG 4 -RD and visualized this with the automated population separation tool of the Infinicyt program. 54 In this analysis we also included a group of patients with treatment-naive sarcoidosis, another fibroinflammatory disease. IgG 4 -RD resembles (Fig 6, A) . This analysis indicates the usefulness of combining multiple parameters for optimal discrimination between patients with IgG 4 -RD and control subjects and potentially from patients with other autoinflammatory conditions with tissue fibrosis. Therefore we continued to develop a score based on the B-and T-cell subsets that were most significantly different between patients with IgG 4 -RD and both control subjects and patients with sarcoidosis (Fig 6, B) . Application of this scoring method to the 56 samples in our study resulted in 50 samples being correctly assigned as either patients without IgG 4 -RD or patients with IgG 4 -RD (Fig 6, B) . between the groups was performed with the Mann-Whitney U test. **P < .01, ***P < .001, and ****P < .0001. Correlation was calculated with Spearman r.
The calculated sensitivity for this score was 93.3% (95% CI, 68.05% to 99.83%), and the calculated specificity was 87.8% (95% CI, 73.80% to 95.92%). Thus patients with IgG 4 -RD carry changes in their blood B-and T-cell subsets that together reflect a unique ''lymphocyte signature.''
DISCUSSION
We demonstrate significant expansions of IgG 4 -expressing B cells in blood of patients with IgG 4 -RD. These changes were related directly to the previously described expansion of CD21 low B cells and are associated with expansions in plasmablasts, T H 2 cells, and Treg cells.
Increased numbers of circulating plasmablasts have been reported before in patients with IgG 4 -RD. 8, 34 This is not a disease-specific effect because similar expansions have been observed in patients with many chronic inflammatory diseases and in those with active infection or after vaccination. [35] [36] [37] [38] Thus increased plasmablast numbers reflect mostly active humoral immune responses. Active inflammation is further supported by the increased numbers of CD21 low B cells in our patients. These cells have been reported to be increased in multiple states of inflammation 43, 55, 56 and are thought to result from prolonged B-cell activity caused by chronic activation by self-antigens.
57
CD21 functions as a coreceptor for the B-cell receptor, and downregulation of its expression makes the cells anergic for chronic stimuli. 58 We now demonstrated that expansion of CD21 low B cells is in part due to expansion of the IgG 4 1 population, which directly links it to the disease. The nature of chronic B-cell stimulation in patients with IgG 4 -RD remains unclear. It is likely that autoantigens are involved because plasmablasts from patients with IgG 4 -RD produce immunoglobulins that react against human cell lysates. 8 Insights into IgG 4 -expressing B cells in patients with IgG 4 -RD are limited, most likely because of the lack of proper reagents to specifically detect and isolate these cells. To overcome this, we developed a flow cytometric approach to staining for IgG 4 -expressing B cells using newly available reagents and found that frequencies and absolute numbers of IgG 4 1 memory B cells were increased in patients with IgG 4 -RD. However, in contrast to previous observations, these numbers were not correlated to IgG 4 serum levels. 59 The absence of correlation is most likely due to the fact that these cells were immunophenotypically memory B cells 60, 61 rather than IgG 4 -producing plasma cells. Previously, we observed similar absence of correlation for IgE 1 memory B-cell numbers and serum IgE levels in patients with atopic dermatitis. 62 In addition to cell numbers, patients' IgG 4 1 memory B cells were phenotypically different from those of healthy control subjects. A lower frequency of cells expressed CD27, which is the conventional marker for memory B cells. 63, 64 Furthermore, expression levels of CXCR5 were lower in patients. These differences could originate from a different maturation pathway for IgG 4 1 memory B cells in patients. Generation of IgG 1 memory B cells in human subjects is critically dependent on T-cell help. 65 Yet it is unclear whether T-cell help is needed for sequential switching to IgG 4 of memory B cells expressing other IgG subclasses. The reduced expression of CXCR5 on IgG 4 1 B cells from patients could represent a reduced capacity for homing to B-cell zones in lymph nodes and would suggest that activation and differentiation of IgG 4 1 B cells in patients occurs in peripheral tissue rather than in lymphoid structures. 66 Cytokines specifically inducing class-switch recombination (CSR) to IgG 4 have been found in tissue biopsy specimens from patients with IgG 4 -RD. 16 Moreover, expression of activation-induced cytidine deaminase, the enzyme that triggers SHM and is needed for CSR, was reported to be increased in tissue biopsy specimens of patients with IgG 4 -RD, conforming the ability of local CSR. 15 In addition to differences in IgG 4 1 memory B cells, we found systemic expansions of T H 2 and Treg cells. Immunoglobulin class-switching to IgG 4 is mediated by the cytokines IL-4 and IL-10, which are predominantly produced by T H 2 and Treg cells, respectively. This is referred to as the ''modified T-helper 2 type response'' 67 and has been reported in the context of the beneficial effects of immunotherapy in allergic patients, in which it favors CSR to IgG 4 over IgE. 68 Indeed, prolonged antigen exposure leads to a serologic shift in the IgG 4 /IgG 1 antibody ratio, as previously illustrated by natural immunization in beekeepers or during subcutaneous immunotherapy with grass pollen. 69, 70 Previous observations in tissue and blood have also linked the modified T H 2-type response to IgG 4 -RD. [16] [17] [18] 20, 69 Our data confirm such a response, with the observation of increased numbers of T H 2 and Treg cells in patients with IgG 4 -RD and a positive correlation between T H 2 cell and IgG 4 1 B-cell numbers. In contrast to earlier observations, we did not find an increase in follicular helper T-cell numbers. 71 Yet this finding supports the hypothesis that differentiation toward IgG 4 in patients with IgG 4 -RD takes place in peripheral tissue rather than in follicles in lymphoid structures. Despite significant differences in numbers of B-and T-cell subsets between patients and control subjects in the presented study, none of these were sufficiently discriminative to be used as a biomarker. This included plasmablasts, which had recently been proposed as a biomarker for IgG 4 -RD. 34 Importantly, numbers of plasmablasts in our patients (median, 3.36 cells/mL) were in the same range as previously reported (median, 4.70 cells/mL), 34 whereas plasmablast numbers were extremely low in control subjects of that study (0.10 cells/mL). 34 Because plasmablasts in our study (median, 1.70 cells/mL) were in the same range as reported by others, it is questionable whether this subset is a reliable biomarker. 72 Therefore we propose to derive a biomarker based on the specific ''lymphocyte signature'' in peripheral blood of patients with IgG 4 -RD. Combined analysis of various subsets has an advantage because it does not rely on one biomarker but rather reflects the pathophysiology of the disease. Because IgG 4 -RD can affect various organs, the clinical presentation is diverse, yet PCA of the peripheral lymphocyte compartment illustrates that the underlying immune response is clearly distinct. This is confirmed by the fact that combined analysis with PCA not only distinguishes health from disease but can also discriminate between different fibroinflammatory conditions (ie, sarcoidosis from IgG 4 -RD). Examples of scoring systems in medical practice are ample, and systems medicine has proved of value to study complex diseases and generate predictive models, although some caution is warranted. 73, 74 In conclusion, we demonstrate that patients with IgG 4 -RD present with increased numbers of IgG 4 1 B cells, CD21 low B cells, and plasmablasts in blood. Molecular characteristics reveal that the latter expansion is a result of an ongoing immune response in affected tissue. Furthermore, this is characterized by increased numbers of T H 2 and Treg cells, which is known as the modified T H 2-type response. This specific peripheral lymphocyte signature in patients with IgG 4 -RD indicates that patients with IgG 4 -RD have a common disease pathogenesis, and in the future, peripheral blood might be exploited as a noninvasive tool for diagnosis and treatment monitoring in patients with IgG 4 -RD. 
